Detalhe da pesquisa
1.
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 389(11): 1009-1022, 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646702
2.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35660812
3.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Cancer
; 130(9): 1663-1672, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127583
4.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Br J Haematol
; 204(5): 1944-1952, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448009
5.
A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Blood
; 139(9): 1289-1301, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34521108
6.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
7.
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk.
Int J Cancer
; 152(2): 239-248, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36082445
8.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Br J Haematol
; 202(4): 866-873, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37376789
9.
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Mod Pathol
; 36(6): 100166, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990279
10.
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Am J Hematol
; 98(10): 1571-1578, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461327
11.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212642
12.
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.
Proc Natl Acad Sci U S A
; 117(33): 20004-20014, 2020 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32747568
13.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med
; 380(22): 2104-2115, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141632
14.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325490
15.
Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms.
Int J Mol Sci
; 23(21)2022 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36362214
16.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
17.
Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.
J Cell Mol Med
; 25(21): 10164-10174, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34651428
18.
New Drugs in Multiple Myeloma.
Annu Rev Med
; 70: 521-547, 2019 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30691369
19.
The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Mod Pathol
; 34(2): 327-335, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32908255
20.
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.
Blood
; 133(14): 1572-1584, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30737236